3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Glioblastoma
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Somatostatinoma
1
Pheochromocytoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Non-hematologic Malignancies
1
Melanoma
1
Kidney Neoplasms
1
Insulinoma
1
Glucagonoma
1
Gliosarcoma
1
Glioma
1
Gastrinoma
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Medullary
1
Carcinoma, Islet Cell
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
pembrolizumab
11
Nivolumab
7
Sunitinib
6
Cyclophosphamide
6
aldesleukin
5
Sorafenib
5
Everolimus
5
temsirolimus
4
belzutifan
4
atezolizumab
4
Ipilimumab
4
fludarabine
3
cabozantinib
3
Interferon-alpha
3
Gene Expression Profiling
3
Fluorouracil
3
Docetaxel
3
Cetuximab
3
Busulfan
3
valspodar
2
sargramostim
2
perifosine
2
pazopanib
2
ixabepilone
2
entinostat
2
ciforadenant
2
belinostat
2
Thiotepa
2
Temozolomide
2
Sirolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Kidney Neoplasms
×
vatalanib
×
Clear all
NCT00303732
2016-03-03
PTK/RAD
Duke University
Phase 1
Completed
37 enrolled